Nexstim has just launched a multicenter double-blinded, randomized, and sham-controlled trial to determine the therapeutic effects of navigated rTMS (repetitive transcranial magnetic stimulation) for stroke rehabilitation. This cutting-edge stroke therapy combines occupational therapy with nTMS (navigated transcranial magnetic stimulation). Called the NICHE trial (Navigated Inhibitory rTMS in Contralesional Hemisphere Evaluation), this study is being conducted at twelve rehabilitation sites in the United States.
Dr. Richard Harvey, Medical Director, Center for Stroke Rehabilitation, Rehabilitation Institute of Chicago (RIC), developed the protocol being used in the NICHE trial and ran the initial trial. Dr. Harvey’s study approached stroke rehabilitation through a new combination of therapies which produced greater gains in patients’ motor function six months post stroke. Using Nexstim’s Navigated Brain Therapy System, the combination of the device’s non-invasive navigated transcranial magnetic stimulation (nTMS) along with occupational therapy opened the door to improving the quality of life for stroke survivors. The study showed over 80% of the active group received a clinically meaningful response rate.
The Navigated Brain Therapy System is CE-marked for patients recovering from stroke as a supplement to conventional rehabilitation.
Nexstim’s noninvasive Navigated Brain Therapy (NBT) System is not approved for Stroke Therapy by the Food and Drug Administration in commercial distribution or use in the United States and is available to select physician for investigational use only.
1Abstract 152 Presented at the American Heart Association/American Stroke Association’s International Stroke Conference February 2014, San Diego: Stroke.2014;45:A152 By: Richard L. Harvey, M.D.; Lynn M. Rogers, PhD; et al